Table 2

 Baseline characteristics of patients included in the study according to clinical response

Responders(n = 83)Non-responders(n = 43)p Value
Anti-CCP, anti-cyclic citrullinated peptide antibodies; DAS 28, disease activity score including 28 joint counts; DMARD, disease-modifying antirheumatic drug; RF, rheumatoid factor.
The values of continuous variables are expressed as median and interquartile range.
*The negative RF samples were included and counted with the measured values.
Age (years)58.35 (48.02–65.55)62.75 (50.5–69.7)0.131
Female/male57/2638/50.017
Disease duration (years)7 (4–12.72)5.5 (2.62–8.93)0.075
Tender joints12 (7–21.5)17 (9.5–24.5)0.106
Swollen joints9 (6–12)8 (5–15)0.457
DAS 285.7 (5–6.42)6.13 (5.32–6.6)0.022
HAQ1.5 (0.87–1.87)1.9 (1.33–2.37)0.002
Previous DMARD, n3 (2–4)3 (2–4)1
Associated DMARD, %92.77 (77/83)83.72 (36/43)0.13
RF (nephelometry), % positive83.13 (69/83)83.72 (36/43)1
    Level*86 (15–268.4)97 (28–338)0.769
IgM RF, % positive78.31 (65/83)83.72 (36/43)0.638
    Level*41.5 (22.1–120)67.6 (32.9–295)0.035
IgA RF, % positive61.44 (51/83)69.76 (30/43)0.434
    Level*24.8 (10.2–90.8)130.4 (13.8–276.7)0.003
IgG RF, % positive57.83 (48/83)69.76 (30/43)0.246
    Level*24.3 (7.2–94.9)46.1 (13.2–210.6)0.057
Anti-CCP, % positive72.28 (60/83)81.39 (35/43)0.285
    Level*25.27 (2.93–74.27)35.28 (7.32–114.99)0.233